Portal de Periódicos da CAPES

Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents

2022; Massachusetts Medical Society; Volume: 386; Issue: 8 Linguagem: Inglês

10.1056/nejmoa2117995

1533-4406

Samantha M. Olson, Margaret M. Newhams, Natasha Halasa, Ashley M. Price, Julie A. Boom, Leila C. Sahni, Pia S. Pannaraj, Katherine Irby, Tracie C. Walker, Stephanie P. Schwartz, Aline B. Maddux, Elizabeth H. Mack, Tamara T. Bradford, Jennifer E. Schuster, Ryan A. Nofziger, Melissa A. Cameron, Kathleen Chiotos, Melissa L. Cullimore, Shira J. Gertz, Emily R. Levy, Michele Kong, Natalie Z. Cvijanovich, Mary Allen Staat, Satoshi Kamidani, Brandon Chatani, Samina Bhumbra, Katherine Bline, Mary Glas Gaspers, Charlotte V. Hobbs, Sabrina M. Heidemann, Mia Maamari, Heidi R. Flori, Janet R. Hume, Matt S. Zinter, Kelly Michelson, Laura D. Zambrano, Angela P. Campbell, Manish M. Patel, Adrienne G. Randolph,

COVID-19 Impact on Reproduction

The increasing incidence of pediatric hospitalizations associated with coronavirus disease 2019 (Covid-19) caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States has offered an opportunity to assess the real-world effectiveness of the BNT162b2 messenger RNA vaccine in adolescents between 12 and 18 years of age.